Zevra Therapeutics (ZVRA)

• Market cap: $453M
• 1 day: -0.59%
• 5 days: -0.93%
• 1 month: -5.35%
• 3 months: 5.33%
• 6 months: 94.72%
• Year to date: 24.30%
• 1 year: 78.74%
• 5 years: 65.82%
• 10 years: -95.26%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Employees: 69

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

231% more call options, than puts

Call options by funds: $6.94M | Put options by funds: $2.1M

121% more capital invested

Capital invested by funds: $90.7M [Q2] → $201M (+$110M) [Q3]

115% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 13

80% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 20

16% more funds holding

Funds holding: 93 [Q2] → 108 (+15) [Q3]

10.77% more ownership

Funds ownership: 44.27% [Q2] → 55.04% (+10.77%) [Q3]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 100% upside
• Avg. target: $21 147% upside
• High target: $25 194% upside

6 analyst ratings

• positive: 6 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Oren Livnat 50% 1-year accuracy 23 / 46 met price target	136% upside $20	Buy Reiterated	20 Nov 2024
Canaccord Genuity Sumant Kulkarni 22% 1-year accuracy 7 / 32 met price target	171% upside $23	Buy Maintained	14 Nov 2024
Guggenheim	136% upside $20	Buy Initiated	7 Oct 2024
JMP Securities Jason Butler 33% 1-year accuracy 13 / 40 met price target	100% upside $17	Market Outperform Initiated	24 Sept 2024
Maxim Group Jason McCarthy 26% 1-year accuracy 7 / 27 met price target	194% upside $25	Buy Maintained	24 Sept 2024